We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $1.8B
1-Year Est. Return 36.16%
This Fund
S&P 500
This Quarter Est. Return
+11.24%
1 Year Est. Return
+36.16%
3 Year Est. Return
+116.66%
5 Year Est. Return
+140.56%
10 Year Est. Return
+771.9%
AUM
$2.96B
AUM Growth
+$159M
Cap. Flow
-$68.1M
Cap. Flow %
-2.31%
Top 10 Hldgs %
19.41%
Holding
293
New
25
Increased
48
Reduced
172
Closed
28

Sector Composition

Rank Sector Weight
1 Industrials 20.32%
2 Healthcare 19.97%
3 Technology 18.44%
4 Consumer Discretionary 14.29%
5 Communication Services 9.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LGND icon
26
Ligand Pharmaceuticals
LGND
$6.02B
$31.5M 1.07%
484,912
-21,242
-4% -$1.42M
SSTK icon
27
Shutterstock
SSTK
$218M
$30M 1.01%
699,206
-19,928
-3% -$799K
CAKE icon
28
Cheesecake Factory
CAKE
$5.34B
$27.6M 0.93%
708,962
+324,587
+84% +$13.4M
ETSY icon
29
Etsy
ETSY
$7.55B
$27.3M 0.92%
+616,506
New +$29.4M
AERI
30
DELISTED
Aerie Pharmaceuticals
AERI
$26.9M 0.91%
1,112,727
+389,102
+54% +$8.06M
ICFI icon
31
ICF International
ICFI
$1.54B
$24.5M 0.83%
267,697
-3,796
-1% -$327K
AIMT
32
DELISTED
Aimmune Therapeutics
AIMT
$24.3M 0.82%
725,431
-26,927
-4% -$753K
OZK icon
33
Bank OZK
OZK
$5.63B
$23.8M 0.81%
781,395
-32,898
-4% -$965K
CRTO icon
34
Criteo S.A. Ordinary Shares
CRTO
$883M
$23.1M 0.78%
1,330,488
-69,568
-5% -$1.24M
ABCB icon
35
Ameris Bancorp
ABCB
$5.92B
$22.9M 0.77%
537,739
+13,318
+3% +$569K
SUPN icon
36
Supernus Pharmaceuticals
SUPN
$2.72B
$22.8M 0.77%
961,973
+24,900
+3% +$605K
PBH icon
37
Prestige Consumer Healthcare
PBH
$2.58B
$22.8M 0.77%
562,815
-14,511
-3% -$541K
NUVA
38
DELISTED
NuVasive, Inc.
NUVA
$22.8M 0.77%
294,329
-4,806
-2% -$339K
OMCL icon
39
Omnicell
OMCL
$1.65B
$22.4M 0.76%
273,557
-4,532
-2% -$348K
IMMU
40
DELISTED
Immunomedics Inc
IMMU
$22.2M 0.75%
1,051,471
+76,614
+8% +$1.35M
CY
41
DELISTED
Cypress Semiconductor
CY
$22M 0.74%
942,626
-142,043
-13% -$3.32M
EPAM icon
42
EPAM Systems
EPAM
$4.86B
$21.8M 0.74%
102,981
-1,624
-2% -$320K
COLL icon
43
Collegium Pharmaceutical
COLL
$944M
$21.7M 0.74%
1,056,386
-159,243
-13% -$2.65M
RETA
44
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$21.3M 0.72%
104,349
-2,619
-2% -$478K
AJRD
45
DELISTED
Aerojet Rocketdyne Holdings
AJRD
$21M 0.71%
460,130
-7,046
-2% -$319K
ECHO
46
DELISTED
Echo Global Logistics, Inc.
ECHO
$20.6M 0.7%
995,742
-54,392
-5% -$1.14M
IAA
47
DELISTED
IAA, Inc. Common Stock
IAA
$20.6M 0.7%
437,274
+125,792
+40% +$5.3M
CALY
48
Callaway Golf Company
CALY
$3.1B
$20M 0.68%
944,565
+118,225
+14% +$2.42M
BSTC
49
DELISTED
BioSpecifics Technologies Corp.
BSTC
$19.8M 0.67%
348,462
-1,806
-0.5% -$95.7K
WLDN icon
50
Willdan Group
WLDN
$1.11B
$19.8M 0.67%
623,881
-79,651
-11% -$2.52M

Similar funds

Rice Hall James & Associates's Q4 2019 Portfolio in Review

As of Q4 2019, Rice Hall James & Associates held 293 positions worth $2.96B, up 5.7% from $2.8B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Rice Hall James & Associates's Q4 2019 filing shows 25 new, 48 increased, 172 reduced and 28 closed positions. Its largest new stake was Etsy: 616,506 shares worth $27.3M. The largest sale was Medidata Solutions, Inc., an estimated $35.2M.

By sector, the portfolio is most concentrated in Industrials at 20% of assets, down from 24% a quarter earlier, followed by Healthcare and Technology.

  • Rice Hall James & Associates's largest Q4 2019 buy was Etsy: 616,506 shares worth $27.3M.
  • Rice Hall James & Associates added most to World Wrestling Entertainment in Q4 2019, an estimated $23.1M increase.
  • Rice Hall James & Associates's biggest Q4 2019 reduction was Premier, cutting an estimated $18.9M.
  • Rice Hall James & Associates fully exited Medidata Solutions, Inc. in Q4 2019, selling an estimated $35.2M.
  • Rice Hall James & Associates's ten largest holdings make up 19% of its $2.96B portfolio in Q4 2019.
  • Rice Hall James & Associates opened 25 new positions and closed 28 in Q4 2019.
  • Rice Hall James & Associates's portfolio value rose 5.7% quarter-over-quarter to $2.96B.

Based on Rice Hall James & Associates's 13F filing for Q4 2019, filed 29 Jan 2020.